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The development of extended-action insulin analogues was motivated by the unfavorable pharmacokinetic (PK) profile
of the conventional long-acting insulin formulations, generally associated with marked inter and intra patient variability
and site- and dose-dependent effect variation. The new ultra-long insulin analogue degludec (IDeg) has the same
amino acid sequence as human insulin except for the removal of threonine in the position 30 of the B chain (Des-B30,
“De”) and the attachment, via a glutamic acid linker (“glu”), of a 16-carbon fatty diacid (hexadecanoic diacid, “dec”) to
lysine in the position 29 of the B chain. These modifications allow that, after changing from the pharmaceutical
formulation to the subcutaneous environment, IDeg precipitates in the subcutaneous tissue, forming a depot that
undergoes a highly predictable gradual dissociation. Thus, once-daily dosing of IDeg results in a low peak: trough ratio,
with consequent low intra-individual variability and plasmatic concentrations less critically dependent upon the time of
injections. The clinical development program of IDeg (BEGIN) was comprised of 9 therapeutic confirmatory trials of
longer duration (26–52 weeks) and showed that the efficacy of IDeg is comparable to insulin glargine in type 1 (T1D)
and type 2 (T2D) diabetes patients across different age, body mass index and ethnic groups. This new ultra-long insulin
analogue presents as advantages flexibility in dose timing and lower risk of hypoglycemia.
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In spite of the body of evidence demonstrating the im-
portance of tight glycemic control in the prevention of
chronic complications of diabetes mellitus (DM), achiev-
ing the targets recommended by the Diabetes Societies’
Guidelines remains a difficult task. Among the reasons
proposed to explain this clinical challenge are factors re-
lated to the disease, such as the progressive nature of
DM, and factors related to the patients, such as lack of
proper diabetes education and, consequently, poor ad-
herence to therapy and self-management. Additionally,
insulin administration by subcutaneous route has intrin-
sic limitations that, together with the pharmacokinetic
(PK) profile of insulin formulations, do not reproduce
the physiological patterns of insulin secretion [1].
Insulin therapy has greatly evolved in the last 40 years
or so; starting with bovine and porcine impure insulin
preparations, to those highly purified (monocomponent
insulins) and to humanized porcine insulin, it was only* Correspondence: freddy.g@uol.com.br
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technology, that insulin could be biosynthesized. Recom-
binant DNA technology paved the way for the synthesis
of insulin analogues, molecules that contain rearrange-
ments in amino acids position to modify the PK profile
of insulin, better mimicking prandial (rapid-acting insu-
lin analogues) and basal (extended-action insulin ana-
logues) insulin secretion [2].
The first successful attempt to prolong the action of
soluble short-term insulin was its non-covalent binding
to protamine, decreasing its solubility at physiological
pH and delaying its absorption from the subcutaneous
tissue, which resulted on intermediate-acting NPH (neutral
protamine Hagedorn) insulin. Addition of varying amounts
of zinc salts without protamine also reduces the solubility
of insulin and originated the Lente family of insulin [3].
The main drawbacks associated with these long-acting
formulations are the substantial inter and intra patient
variability, accounting for a large proportion of the day-
to-day glycemic fluctuation [4]; their marked site- and
dose-dependent effect variation; and the variability associ-
ated with the magnitude of resuspension before injectionOpen Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ity of insulin therapy to cause hypoglycemia and weight
gain, stimulated the development of the new insulin
analogues, glargine and detemir. Glargine (IGlar) is a di-
arginyl insulin analogue whose isoeletric point increased
from 5.4 towards a neutral pH, with consequent precipi-
tation at the site of injection, delayed absorption and
prolonged effect. The mechanism of protraction of dete-
mir involves deletion of Thr B30 and covalent acylation
of Lys B29, that determines reversible binding of insulin
to albumin, delayed absorption and prolonged effect [2].
Structure and properties underlying the mechanism of
insulin protraction in degludec formulation
During the synthesis process in pancreatic β-cells, insu-
lin molecules self-associate into dimers that, in presence
of zinc, assemble into hexamers (comprised of three di-
mers arranged around two zinc ions) allowing efficient
storage into the secretory granules. After exocytosis, di-
lution immediately dissociates the hexamers in dimmers,
and then in the biologically active monomers [6]. These
properties of hexamers formation and dissociation are
exploited for the pharmaceutical development of insulin
analogues to accelerate or slow down the rate at which
insulin leaves the subcutaneous injection site to blood-
stream [7].
The new ultra-long insulin analogue degludec (IDeg)
has the same amino acid sequence as human insulin ex-
cept for the removal of threonine in the position 30 of
the B chain (Des-B30, “De”) and the attachment, via a
glutamic acid linker (“glu”), of a 16-carbon fatty diacid
(hexadecanoic diacid, “dec”) to lysine in the position 29
of the B chain (Fig. 1). In IDeg formulation, the presence
of zinc and resorcinol determines the formation of hex-
amers, and the presence of zinc and phenol determines
the formation of dihexamers. After IDeg injection, phe-
nol depletion promotes the self-association of dihexa-
mers to form linear multihexamers, which precipitate in
the subcutaneous tissue [8] (Fig. 2). The acylation of ly-
sine B29 also participates in the protraction mechanism,
permitting binding to albumin in the bloodstream, like
insulin detemir [9]. Slow dispersion of zinc ions fromFig. 1 The structural formula of insulin degludec. Adapted from Referencethe subcutaneous depot allows a highly predictable grad-
ual dissociation into insulin monomers, which behave
exactly like human insulin regarding insulin receptor
binding and activation and the subsequent metabolic ef-
fects. Following IDeg injection, insulin concentrations
rise immediately but slightly, achieving maximum plas-
matic concentration (Cmax) after 10–12 h; the mean ter-
minal half-life (t1/2) of 17–25 h is almost twice as that of
IGlar, until now the longest-acting insulin analogue
(Fig. 1) [10].
IDeg concentrations achieve steady state after 2–3 days
of once-daily administration with no further accumulation
thereafter because, from that point, the daily-injected dose
equals the daily-eliminated amount of insulin when re-
peated equivalent doses are administered at adequate
intervals [11].
Concerning intra-individual variability, the insulin ana-
logues IGlar and detemir already present lower within-
subject variability than NPH, as demonstrated by Heise
et al. in type 1 diabetes (T1D) patients distributed in
three groups for receiving each one of these long-acting
formulations (0.4 U/kg once daily on four identical study
days) under euglycemic clamp conditions. The coeffi-
cient of variation (CV) for the pharmacodynamic end-
point GIR-AUC (0-24h) (area under the curve for glucose
infusion rates from 0–24 h) was 68 % for NPH, 48 % for
IGlar and 27 % for detemir [12]. Heise et al. [13] also
compared intra-individual variability between IDeg and
IGlar in T1D patients, now under steady-state condi-
tions (which might explain the different results observed
for IGlar), in 24-h euglycemic clamps performed on the
6th, 9th and 12th day of treatment with 0.4 U/kg of each
one of the insulin preparations. The CV for GIR-AUC
(0-24h) was 20 % for IDeg and 82 % for IGlar (Fig. 3); this
difference is probably related to their distinct mechan-
ism of protraction; the IDeg multihexamers at the injec-
tion site dissociate slowly to release monomers while
IGlar micro precipitates formed at the injection site
must re-dissolve before absorption, a process inherently
variable.
The clinical implications of the aforementioned phar-
macodynamic and PK properties of IDeg at steady-state[15]
Fig. 2 In the solvent conditions in insulin degludec formulation, the presence of zinc and resorcinol determines the formation of hexamers, and
the presence of zinc and phenol determines the formation of dihexamer (upper panel). In the subcutaneous tissue after insulin degludec
injection, phenol depletion promotes the self-association of dihexamers to form linear multihexamers, which will precipitate (lower panel). The
black bars between degludec hexamers represent the acyl modification of LysB29. Adapted from Reference [8] (Steensgaard et al.)
Fig. 3 Day-to-day variability in the glucose - lowering effect of
insulin degludec (IDeg) and insulin glargine (IGlar) over 24 h at
steady state as shown by the coefficient of variation (CV) for the
pharmacodynamic endpoint (area under the curve for glucose infusion
rates from 0–24 h). Adapted from Reference [13] (Heise et al.)
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and consequent less variability of action and plasmatic
concentrations less critically dependent upon the time of
injections, permitting flexibility in dose timing [14].
Clinical development program (BEGIN)
The clinical development program of IDeg included 3
therapeutic exploratory trials of short duration (6–16
weeks) and 9 therapeutic confirmatory trials of longer
duration (26–52 weeks). The primary objectives of the
trials were to confirm the efficacy of IDeg administered
once daily in controlling glycemia (change from baseline
in HbA1c). Table 1 summarizes the studies conducted in
T2D (6 studies; n =2733 receiving IDeg and n =1343 re-
ceiving active comparators) and in T1D (3 studies; n =1104
receiving IDeg and n =474 receiving active compara-
tors). All confirmatory trials were randomized, controlled,
parallel-group, open-label, multicenter, multinational and
treat-to-target in which IDeg was compared to an active
comparator; 5 of the confirmatory trials (3 in T1D and 2
in T2D) were extended for further periods of 26 or
52 weeks to evaluate long-term safety. One trial in T1D
and one trial in T2D included a third treatment arm in
which IDeg was administered in the morning and in the
Table 1 Overview of the therapeutic confirmatory trials of degludec in patients with Type 1 and Type 2 diabetes mellitus
Trial Population Therapy Treatment arms Treatment
combination
Duration (Weeks) Treatment at screening
3582 Insulin-treated
T2D
Basal-bolus Degludec OD + Aspart 52 Any insulin regimen
versus ± Met (Extension of 26 wks)
Glargine OD ± Pio
3579 Insulin-naïve Insulin + OADs Degludec OD + Met 52 Met (mandatory) ± SU, ±a-GI,
± DPP-4i in any combination
T2D versus ± DPP-4i (Extension of 52 wks)
Glargine OD
3672 Insulin-naïve Insulin + OADs Degludec OD + Met 26 Met (mandatory) ± SU, ± α-GI,
± DPP-4i in any combination
T2D versus ± DPP-4i
Glargine OD
3586 Insulin-naïve Insulin + OADs Degludec OD ± Met 26 Monotherapy or combination
of SU and Met ± α-GI, or DPP-4i
T2D versus ± SU
Glargine OD ± α-GI
3580 Insulin-naïve Insulin + OADs Degludec OD +1-2 ADOs: Met, SU,
Pio
26 ± Met, ± SU, ± pio 1–2 OADs
in any combination
T2D versus
Sitagliptin OD
3668 Insulin-naïve +
insulin -treated
Insulin + OADs Degludec Fixed
Flex OD versus
± Met 26 OADs only or basal insulin
only or basal insulin + OADs
(any combination of Met,
SU or Pio)T2D Glargine OD and
Degludec Fixed Flex OD
± SU
versus ± Pio
Degludec OD
3583 Insulin- treated Basal-bolus Degludec OD + Aspart 52 Any basal-bolus regimen
T1D versus (Extension of 52 wks)
Glargine OD
3585 Insulin- treated Basal-bolus Degludec OD + Aspart 26 Any basal-bolus regimen
T1D versus (Extension of 26 wks)
Detemir OD
3770 Insulin- treated Basal-bolus Degludec Fixed Flex OD + Aspart 26 Any basal-bolus regimen
T1D versus (Extension of 26 wks)
Glargine OD and Degludec
Fixed Flex OD versus
Degludec OD
α-GI alpha-glucosidase inhibitor, Dpp-4i dipeptidyl peptidase-4 inhibitor, Met metformin, OADs oral antidiabetic drugs, OD once daily, Pio pioglitazone, SU sulpho-
nylurea, T1D type 1 diabetes, T2D Type 2 diabetes, Wks weeks
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schedule) aiming at evaluating the impact of extreme day-
to-day variation in the dosing intervals (from 8–12 h to
36–40 h).
The inclusion criteria concerning antidiabetic therapy
and disease duration (mean of 17.3 years for T1D and
10.5 years for T2D) ensured that all subjects were eli-
gible for intensified treatment. The HbA1c limits were
7.0 or 7.5 to 10 or 11.0 % (mean of 7.8 % for T1D and
8.4 % for T2D) and the upper limits for body mass index
(BMI) were 35.0 for T1D and 40.0 kg/m2 for T2D (ex-
cept in Trial 3586, that included Asian subjects, forwhom the upper limit was 35.0 kg/m2 and Trial 3672, in
which the upper limit was 45.0 kg/m2). Insulin-naïve pa-
tients with T2D started once daily basal insulin at a dose
of 10 U/day while in insulin-treated subjects, a unit-to-
unit transfer was recommended, with adjustments per-
formed at the investigator’s discretion.
The changes in HbA1c observed in the therapeutic
confirmatory trials are shown in Fig. 4; efficacy of IDeg
was demonstrated in T1D and T2D patients across dif-
ferent age, BMI and ethnic groups, and in combination
with different OADs. The Fixed Flexible dose schedule
was as effective as IDeg dosed every day in the evening
Fig. 4 Mean values of HbA1c observed in the 9 therapeutic confirmatory trials at baseline and at end of trial (EOT) for insulin degludec (IDeg)
and comparators (insulin glargin, except in trials 3585 [insulin determir] and 3580 [sitagliptin]). FF: Fixed-flexible schedule; OADs: oral antidiabetic
drugs; T1D: Type 1 diabetes; T2D: Type 2 diabetes. Adapted from Reference [15]
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firmed nocturnal hypoglycemia was lower with IDeg
than with IGlar in T2D (Fig. 5), while no significant dif-
ferences were observed in T1D patients, this analysis
was probably affected by the low number of severe noc-
turnal episodes observed along the clinical trials [15].
The risk of hypoglycemia in T2D patients was add-
itionally evaluated in a meta-analysis of 5 confirmatory
trials (3582, 3579, 3672, 3586, 3668) that considered the
subset of subjects who required high basal insulin doses
(>60 U) at the end of the studies (n = 795 patients
receiving IDeg versus n = 374 receiving IGlar for 26 orFig. 5 The frequency of confirmed nocturnal hypoglycemia (between 00:0
glargin, except in trial 3580 [sitagliptin]) in Type 2 diabetes patients particip
PYE: patient years of exposure; T1D: Type 1 diabetes; T2D: Type 2 diabetes.52 weeks). Patients in the two treatment arms achieved
similar mean HbA1c values (7.2 %), while mean fast-
ing plasma glucose was significantly lower with IDeg
(115,4 mg/dL) than with IGlar (119,8 mg/dL, P = .04).
Lower rates of overall confirmed hypoglycemic epi-
sodes and nocturnal confirmed hypoglycemic epi-
sodes were observed with IDeg in comparison to
IGlar (P < .01) [16].
The results of 3 confirmatory trial extensions have
been recently published. In Trial 3579 (BEGIN Once
Long), 505 of the 773 randomized insulin-naive T2D pa-
tients completed 104 weeks of study (52-week main1 and 5:59 am) with insulin degludec (IDeg) and comparators (insulin
ating in 6 therapeutic confirmatory trials. FF: Fixed-flexible schedule;
Adapted from Reference [15]
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from 8.1 ± 0.8 % and 8.2 ± 0.8 % at baseline to 7.0 ± 0.9 %
and 6.9 ± 0.8 % at 104 weeks with IDeg and IGlar, respect-
ively. Overall confirmed hypoglycemia rates were similar
between IDeg and IGlar when considering the entire trial
period, but nocturnal confirmed hypoglycemia was 43 %
lower with IDeg at the end of 104 weeks (rate ratio [RR,
expresses the relative chance of hypoglycemia in the group
of patients receiving degludec as compared with the group
receiving glargine] of 0.57, 95 % confidence interval [CI]
0.40-0.81, P = .002) as well as severe hypoglycemia (RR of
0.31, 95 % CI 0.11-0.85, P = .023) [17].
In Trial 3583 (BEGIN Basal-Bolus Type 1) 469 of the
629 randomized T1D patients completed 104 weeks of
study (52-week main study + 52-week extension period).
Mean HbA1c decreased from 7.7 % at baseline in both
groups to 7.4 % and 7.5 % at 104 weeks with IDeg and
IGlar, respectively; these results were achieved with pa-
tients in the IDeg treatment arm receiving 12 % less
basal and 9 % less total daily insulin than patients in
the IGlar treatment arm (P < .01). Overall confirmed
hypoglycemia rates were similar between IDeg and
IGlar when considering the entire trial period, but noc-
turnal confirmed hypoglycemia was 25 % lower with
IDeg at the end of 104 weeks (RR of 0.75, 95 % CI
0.59-0.95, P = .02) [18].
Finally, in Trial 3770 (BEGIN: Flex T1) the Fixed Flex-
ible dose schedule of IDeg was compared to IDeg or to
IGlar, both given at the same time daily for 26 weeks to
T1D patients. In the 26-week extension period, all IDeg
patients were shifted to a free-flexible schedule (Free-
Flex; dosing allowed at any time of the day) and com-
pared with patients who continued on IGlar. Mean
HbA1c decreased from 7.7 % at baseline in all three
groups by −0.40 %, −0.41 % and −0.58 % points with
IDeg Fixed Flexible, IDeg and IGlar, respectively at week
26. At the end of the extension period, HbA1c was 7.6 %
in the IDeg Free Flex treatment arm and 7.5 % in the
IGlar treatment arm, and mean daily basal, bolus and
total insulin doses were lower by 4 %, 18 % and 11 %, re-
spectively with IDeg Free Flex. Confirmed and severe
hypoglycemia rates were similar among the three groups
after 26 weeks, but nocturnal confirmed hypoglycemia
was lower with IDeg Fixed Flex than with IGlar (by 40 %)
and IDeg (by 37 %). At week 52, nocturnal confirmed
hypoglycemia was 25 % lower with IDeg Free-Flex than
with IGlar (P = .026) [19].
Still regarding IDeg and hypoglycemia, a double-blind
randomized crossover study using stepwise hypoglycemic
clamp has demonstrated that symptomatic and cognitive
responses to induced hypoglycemia, as well as the time re-
quired for glycemia recovery are similar between IDeg and
IGlar, reassuring the safety profile of IDeg with respect to
hypoglycemic awareness [20].Use in special populations
The evaluation of the PK profile of IDeg after a single
dose in diabetic and non-diabetic subjects presenting
normal hepatic function and mild (Child–Pugh grade A),
moderate (Child–Pugh grade B) or severe (Child–Pugh
grade C) hepatic impairment revealed no differences in
the AUC120-h of plasmatic IDeg concentration–time curve,
in Cmax and in the apparent clearance (CL/F) for individ-
uals with impaired versus normal hepatic function. Differ-
ences in serum albumin concentrations did not interfere
with the AUC 120-h [21].
PK of a single dose of IDeg was also evaluated in sub-
jects with renal impairment with or without DM (cre-
atinine clearance [CLCR] estimated by the Cockcroft
and Gault formula: CLCR 50–80 mL/min [mild], CLCR
30–49 mL/min [moderate], CLCR <30 mL/min [severe]
or end-stage renal disease requiring hemodialysis) in
comparison to subjects with normal renal function
(CLCR >80 mL/min). Again, no differences were ob-
served in the AUC120-h, in Cmax and in CL/F for individ-
uals with impaired versus normal renal function [22].
One possible explanation for these findings is that al-
though the liver and kidneys participate in insulin clear-
ance, it also requires internalization of the insulin
receptor in the target cells, a process that might be more
prevailing in albumin-bound insulins that are not filtered
by the kidney as readily as unbound insulins. Thus, hep-
atic and renal impairment do not significantly interfere
with the PK properties of these insulin analogues [23].
With respect to the elderly population, there were only
minor differences in the PK properties of IDeg between
young and elderly subjects [15]. A recent meta-analysis
assessed the frequency of hypoglycemia in 917 T1D and
T2D patients ≥ 65 years of age who participated in 7
confirmatory trials comparing IDeg and IGlar (3582,
3579, 3672, 3586, 3668, 3583, 3770). In the pooled popu-
lation of T1D + T2D patients, rates of confirmed noctur-
nal hypoglycemia were 35 % lower with IDeg than IGlar
for the total treatment period (OR 0.65, CI 95 % 0.46-
0.93, P < .05) [24].
Based on the results from the clinical studies, the type,
frequency and severity of adverse reactions observed in
elderly patients and in those with renal or hepatic im-
pairment are not different from the general population
[15].
Conclusions
IDeg is an ultra-long insulin analog that exhibits low
intra-individual variability and whose efficacy is compar-
able to IGlar, but which presents as advantages flexibility
in dose timing and lower risk of hypoglycemia, benefits
that may impact quality of life and adherence to therapy
[25]. Thus, this ultra-long insulin analog is a relevant
addition to the therapeutic armamentarium for diabetes.
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